PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 7, 2025New England Journal of Medicine96 citationsOpen Access

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

SNStephen J. NichollsANAdam J. NelsonMDMarc Ditmarsch

Key Points

  • To assess the efficacy and safety of obicetrapib in lowering LDL cholesterol among patients at high cardiovascular risk receiving maximally tolerated lipid-lowering therapy.
  • Interventional clinical trial (BROADWAY; ClinicalTrials.gov number, NCT05142722).
  • Evaluated patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia on maximum tolerated doses of lipid-lowering therapy.
  • Obicetrapib reduced LDL cholesterol levels by 29.9% in patients at high risk for cardiovascular events.

Abstract

Among patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were receiving maximum tolerated doses of lipid-lowering therapy and were at high risk for cardiovascular events, obicetrapib reduced LDL cholesterol levels by 29.9%. (Funded by NewAmsterdam Pharma; BROADWAY ClinicalTrials.gov number, NCT05142722.).

Expert Takes1 quote

“We still have too many high-risk patients who do not get their LDL to goal. Obicetrapib has the potential additional tool for those patients.”

Medscape CardiologyView source
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nicholls et al. (2025) studied this question.

synapsesocial.com/papers/69d6c632fca0359822aa86b5https://doi.org/10.1056/nejmoa2415820
Ask AI
Helpful
Bookmark
Share
View Full Paper